Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What CAGR And Valuation Are Anticipated For The Chikungunya Market?

Over the past few years, the chikungunya market has experienced considerable growth. Its expansion is predicted to continue, rising from $0.59 billion in 2024 to $0.65 billion in 2025, with a compound annual growth rate (CAGR) of 9.4%. This growth during the historical period can be credited to factors such as an increase in individual healthcare spending, a surge in newly emerging and re-emerging infectious disease cases, rising personal disposable income, changes in climate, and heightened awareness about mosquito-borne diseases.

In the coming years, a substantial expansion is projected for the chikungunya market. By 2029, the market size is set to hit $0.92 billion with a compound annual growth rate (CAGR) of 9.2%. The growth forecast can be linked to various factors such as an upsurge in international clinical trials, an expanding aged population, escalated immunization requirements, rising initiatives from the government and other organizations, increased government investments, and beneficial policies. Also, major trend indicators during the forecasted period include the advancement in biotechnological processes in vaccine development, fresh opportunities in the vaccine sector, utilization of CRISPR and AI in innovative solutions, strategic alliances among pharmaceutical giants, and the inclusion of telemedicine services.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21137&type=smp

What Are The Primary Factors Supporting The Chikungunya Market Expansion?

The increasing occurrence of diseases transmitted by mosquitoes is forecasted to stimulate the expansion of the chikungunya market in the future. Mosquito-borne ailments, for example, chikungunya, dengue, and zika virus, which are circulated to humans through infected Aedes mosquitoes, present considerable worldwide public health challenges. Rising global incidences of these diseases can be attributed to factors such as climate change, urban growth, deforestation, the buildup of stagnant water, insufficient vector control strategies, elevated levels of international travel, and a resistance to insecticides. Treatments for chikungunya help patients suffering from mosquito-borne diseases by alleviating symptoms like fever, joint pain, and inflammation, which enhances the patient’s overall level of comfort and mobility, mitigates the likelihood of complications, and speeds up recovery through measures like hydration, pain management, and supportive care. For instance, the UK Health Security Agency, a UK government agency, reported in December 2024 that between January and June 2024, dengue cases among returning travelers in England, Wales, and Northern Ireland rose to 473, presenting a 201% increase from the 157 cases reported over the same time frame in 2023. As a result, the escalating global instances of mosquito-borne diseases are stimulating the expansion of the chikungunya market.

Which Segments Define The Structure Of The Chikungunya Market?

The chikungunyamarket covered in this report is segmented –

1) By Type: Antiviral Drugs; Herbal And Complementary Treatments; Supportive Care; Vaccines

2) By Product Form: Liquid Form; Powder; Solid Form

3) By Disease Stage: Acute; Chronic; Post-Infection

4) By Sales Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies; Supermarkets

5) By End User: Caregivers; Healthcare Professionals; Patients

Subsegments:

1) By Antiviral Drugs: Nucleoside Analogues; Protease Inhibitors

2) By Herbal And Complementary Treatments: Ayurvedic Remedies; Homeopathic Treatments; Traditional Chinese Medicine

3) By Supportive Care: Pain Relievers (NSAIDs, Acetaminophen); Fluid Therapy; Physiotherapy

4) By Vaccines: Live-Attenuated Vaccines; Inactivated Vaccines; mRNA-Based Vaccines

What Strategic Shifts And Innovations Are Influencing The Chikungunya Market?

Leading players in the chikungunya market are channeling their efforts to create innovative vaccines to boost immunity, subdue potential epidemics, and handle the rising worldwide health issue of chikungunya virus infection. A live attenuated chikungunya vaccine leverages a weakened version of the chikungunya virus to trigger an immune reaction without provoking the disease, thus providing durable resistance. For example, Valneva SE, a biotech firm based in France, announced in November 2023 that the US-based government agency, Food and Drug Administration (FDA), had approved its live attenuated chikungunya vaccine, IXCHIQ. The FDA granted the approval rapidly based on anti-CHIKV neutralizing antibody titers, with continuing approval reliant on the confirmation of clinical benefits in supplementary studies. Valneva secured a Priority Review Voucher (PRV) from the FDA, which it plans to leverage in financing its research and development initiatives. Ixchiq is administered as a single-dose muscle injection, containing a live, attenuated version of the chikungunya virus, which could lead to symptoms in recipients mirroring those of chikungunya sickness.

Who Are The Primary Market Leaders In The Chikungunya Market?

Major companies operating in the chikungunya market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Quest Diagnostics Incorporated, Eurofins Scientific SE, Grifols Diagnostic Solutions Inc., bioMérieux SA, Bio-Rad Laboratories Inc., DiaSorin S.p.A., Euroimmun AG, Evotec SE, Valneva SE, ELITechGroup S.A.S., Vaxart Inc., BioPerfectus Biotechnology Co. Ltd., CTK Biotech Inc., Creative Diagnostics Inc., Inovio Pharmaceuticals Inc., Biotrol Laboratories Pvt. Ltd.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/chikungunya-global-market-report

What Regional Factors Are Accelerating Growth In The Chikungunya Market?

North America was the largest region in the chikungunya market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chikungunya market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=21137&type=smp

Browse Through More Reports Similar to the Global Chikungunya Market 2025, By The Business Research Company

Respiratory Disease Testing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/respiratory-disease-testing-global-market-report

Respiratory Disease Vaccine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/respiratory-disease-vaccine-global-market-report

Artificial Intelligence Ai In Respiratory Diseases Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-in-respiratory-diseases-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model